Nicholas Mollanazar, MD, MBA
Basic profileUniversity of Pennsylvania Health System
Nicholas Mollanazar is a Dermatology physician affiliated with University of Pennsylvania Health System. OpenAlex indexes 54 publications with 1,842 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 Spruce Street
10th Floor
Philadelphia, PA 191075701
Telephone
941-718-8997Provider last certified this registry record 8 Jan 2025.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202522 payments$100,482openpaymentsdata.cms.gov ↗
- UCB, Inc.Program year202518 payments$18,066openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202514 payments$10,756openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
50.4%Corticosteroid25%Triamcinolone Acetonide92%Fluocinolone Acetonide8%Part D≥213 patientsInterleukin-4 Receptor alpha Antagonist19.2%Dupixent Pen76%Dupixent Syringe24%Part D<11 patients+ 5 more classes in this area
Sensory organs
20.9%Corticosteroid20.9%Clobetasol Propionate100%Part D≥160 patientsAnti-infectives
15.3%Tetracycline-class Drug5.2%Doxycycline Hyclate76%Doxycycline Monohydrate24%Part D≥43 patientsLincosamide Antibacterial4.7%Clindamycin Phosphate100%Part D≥29 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Adalimumab biosimilars and access barriers in dermatology
Journal of the American Academy of Dermatology
2026 - Prurigo nodularis: disease burden, clinical features and approach to management
British Journal of Dermatology
2025 - Achievement of Optimal Treatment Targets with Oral Janus Kinase Inhibition in Elderly Patients with Atopic Dermatitis: A Real-world, Multicenter, Retrospective Study.
PubMed
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Jerome Strauss, MD, PhD
University of Pennsylvania Health System
Arthur Staddon, MD
University of Pennsylvania Health System
Keith Calligaro, MD
University of Pennsylvania Health System
Fiona Simpkins, MD
University of Pennsylvania Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”